ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
The Lancet Oncology
◽
10.1016/s1470-2045(13)70026-3
◽
2013
◽
Vol 14
(3)
◽
pp. 228-235
◽
Cited By ~ 112
Author(s):
John FR Robertson
◽
Jean-Marc Ferrero
◽
Hugues Bourgeois
◽
Hagen Kennecke
◽
Richard H de Boer
◽
...
Keyword(s):
Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Phase 2
◽
Double Blind
◽
Phase 2 Trial
◽
Hormone Receptor Positive
◽
Randomised Controlled
◽
Positive Breast Cancer
Download Full-text
Related Documents
Cited By
References
Faculty of 1000 evaluation for Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.
F1000 - Post-publication peer review of the biomedical literature
◽
10.3410/f.717985574.793472568
◽
2013
◽
Author(s):
Ana Maria Gonzalez-Angulo
Keyword(s):
Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Phase 2
◽
Double Blind
◽
Phase 2 Trial
◽
Hormone Receptor Positive
◽
Randomised Controlled
◽
Positive Breast Cancer
Download Full-text
Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer
10.1158/1538-7445.sabcs16-p2-08-01
◽
2017
◽
Author(s):
I Krop
◽
V Abramson
◽
M Colleoni
◽
FA Holmes
◽
L Estevez
◽
...
Keyword(s):
Breast Cancer
◽
Hormone Receptor
◽
Phase 2
◽
Phase 2 Trial
◽
Hormone Receptor Positive
◽
Positive Breast Cancer
Download Full-text
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
Clinical Cancer Research
◽
10.1158/1078-0432.ccr-11-0070
◽
2011
◽
Vol 17
(21)
◽
pp. 6897-6904
◽
Cited By ~ 63
Author(s):
Erica L. Mayer
◽
Jean-Francois Baurain
◽
Joseph Sparano
◽
Lewis Strauss
◽
Mario Campone
◽
...
Keyword(s):
Breast Cancer
◽
Hormone Receptor
◽
Phase 2
◽
Her2 Positive
◽
Phase 2 Trial
◽
Hormone Receptor Positive
◽
Positive Breast Cancer
Download Full-text
Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases
10.1158/1538-7445.sabcs16-ot1-04-05
◽
2017
◽
Author(s):
HS Rugo
◽
KC Drumea
◽
M Campone
◽
A Barnadas
◽
O Petrenciuc
◽
...
Keyword(s):
Breast Cancer
◽
Bone Metastases
◽
Hormone Receptor
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Radium 223
◽
Positive Breast Cancer
Download Full-text
Abstract S1-4: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of AMG 479 With Exemestane (E) or Fulvestrant (F) in Postmenopausal Women With Hormone-Receptor Positive (HR+) Metastatic (M) or Locally Advanced (LA) Breast Cancer (BC)
10.1158/0008-5472.sabcs10-s1-4
◽
2010
◽
Cited By ~ 16
Author(s):
PA Kaufman
◽
JM Ferrero
◽
H Bourgeois
◽
H Kennecke
◽
R De Boer
◽
...
Keyword(s):
Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Locally Advanced
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Phase 2 Study
Download Full-text
Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer
10.1158/1538-7445.sabcs17-gs4-07
◽
2018
◽
Cited By ~ 6
Author(s):
I Krop
◽
V Abramson
◽
M Colleoni
◽
T Traina
◽
F Holmes
◽
...
Keyword(s):
Breast Cancer
◽
Hormone Receptor
◽
Phase 2
◽
Phase 2 Trial
◽
Hormone Receptor Positive
◽
Positive Breast Cancer
Download Full-text
A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.tps621
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. TPS621-TPS621
◽
Cited By ~ 1
Author(s):
Hope S. Rugo
◽
Rui Li
◽
Oana Petrenciuc
◽
Amily Zhang
◽
Robert E. Coleman
Keyword(s):
Breast Cancer
◽
Bone Metastases
◽
Hormone Receptor
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Radium 223
◽
Positive Breast Cancer
Download Full-text
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
The Lancet Oncology
◽
10.1016/s1470-2045(19)30786-7
◽
2020
◽
Vol 21
(1)
◽
pp. 33-43
◽
Cited By ~ 16
Author(s):
Aleix Prat
◽
Cristina Saura
◽
Tomás Pascual
◽
Cristina Hernando
◽
Montserrat Muñoz
◽
...
Keyword(s):
Breast Cancer
◽
Postmenopausal Women
◽
Hormone Receptor
◽
Phase 2
◽
Open Label
◽
Luminal B
◽
Phase 2 Trial
◽
Hormone Receptor Positive
Download Full-text
A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases
Annals of Oncology
◽
10.1093/annonc/mdw365.89
◽
2016
◽
Vol 27
◽
pp. vi97
◽
Cited By ~ 1
Author(s):
H. Rugo
◽
O. Petrenciuc
◽
A. Zhang
◽
R. Li
◽
R.E. Coleman
Keyword(s):
Breast Cancer
◽
Bone Metastases
◽
Hormone Receptor
◽
Controlled Trial
◽
Phase 2
◽
Double Blind
◽
Double Blind Placebo
◽
Hormone Receptor Positive
◽
Radium 223
◽
Positive Breast Cancer
Download Full-text
Abstract PS9-71: The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer
10.1158/1538-7445.sabcs20-ps9-71
◽
2021
◽
Author(s):
Rukiye Guler Ilhan
◽
Yusuf Ilhan
◽
Sema Sezgin Goksu
◽
Ali Murat Tatli
◽
Hasan Senol Coskun
Keyword(s):
Breast Cancer
◽
Postmenopausal Women
◽
Aromatase Inhibitors
◽
Cognitive Functions
◽
Hormone Receptor
◽
Hormone Receptor Positive
◽
Positive Breast Cancer
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close